-+ 0.00%
-+ 0.00%
-+ 0.00%
Pharming Reports Preliminary Q3 Revenues $117.6M, Up 21% YoY; Operating Expenses $74.6M Vs $74.5M YoY; Napazimone FALCON Trial Enrollment Now Expected Complete In First Half 2027, 2026 Revenue Guidance Tightened To $380M-$390M From $375M-$395M
Share
Listen to the news
  • Third quarter 2026 total revenues increase by 21% to approximately US$117.6 million, compared to third quarter 2025
  • Third quarter 2026 total operating expenses of approximately US$74.6 million, in line with third quarter 2025
  • Tightened 2026 total revenue guidance to US$380 million - US$390 million from prior US$375 million - US$395 million
  • Full third quarter financial results and business update brought forward to October 27, 2026; conference call and webcast for analysts and investors to follow at 13:30 CET/08:30 EDT
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending